Pazopanib

CAT: 0804-HY-10208-01Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-10208-01Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

CAS Number

444731-52-6

Product Name Alternative

GW786034

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; c-Kit; FGFR; PDGFR; VEGFR

Type

Reference compound

Related Pathways

Autophagy; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Pazopanib.html

Purity

99.91

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=S(C1=CC(NC2=NC=CC(N(C3=CC4=NN(C(C)=C4C=C3)C)C)=N2)=CC=C1C)(N)=O

Molecular Formula

C21H23N7O2S

Molecular Weight

437.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Harris PA, et al. Discovery of 5-[[4-[ (2,3-dimethyl-2H-indazol-6-yl) methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008, 51 (15), 4632-4640.|[2]Thakur A, et al. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011 Nov;82 (3) :346-50.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

PDGFRβ; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4

Citation 01

Alternative Products

Catalog	Name
MBS808205-01	Pazopanib

Pazopanib

Alternative Products

Popular Products